NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients

Fore Biotherapeutics20 enrolled

Overview

NovellusDx technology identifies tumor-specific driver mutations, but unlike sequencing-based tests, NovellusDx has a functional assay that detects dis-regulated translocation of mutated signaling proteins to the nucleus. This allows NovellusDx to identify functionally-impactful driver mutations regardless of whether the mutation has previously been described or linked to a tumor type.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Lung Cancer

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients that are suspected to have lung cancer and are eligible for biopsy, surgical intervention or pleural fluid suction Exclusion Criteria: * Patients without lung cancer

Locations (1)

Rabin Medical Center, Beilinson

Petah Tikva, Israel

Outcomes

Primary Outcomes

Correct identification of tumor mutant genes

Correct identification of patient oncogenic mutation in over 85% of the cases. this will be achieved by comparing sequencing results of the patient tumors to the results achieved using the NovellusDx diagnostic platform.

Time frame: up to 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.